Trevi Therapeutics Schedules May 7 NYC Investor Day, May 12 BofA Presentation and May 18 ATS Session
Trevi Therapeutics will host an in-person Investor and Analyst Day in New York City on May 7, featuring senior management and key opinion leaders in chronic cough. The company will present at the Bank of America Global Healthcare Conference in Las Vegas on May 12 and share ATS 2026 data highlights in Orlando on May 18.
1. Investor and Analyst Day in New York
On May 7, Trevi Therapeutics will convene an in-person Investor and Analyst Day in Midtown Manhattan from 10:00 a.m. to 12:00 p.m. ET, followed by lunch and open discussions. Senior management will be joined by leading chronic cough experts to discuss Haduvio’s clinical trial progress in IPF, non-IPF ILD and refractory chronic cough.
2. Bank of America Global Healthcare Conference
Trevi’s President and CEO Jennifer Good and CFO David Hastings will deliver a corporate presentation at the Bank of America Global Healthcare Conference in Las Vegas on May 12 from 5:15 p.m. to 5:30 p.m. PT. The 15-minute session will outline the company’s development milestones for its oral nalbuphine ER therapy.
3. ATS 2026 Data Highlights Session
On May 18 in Orlando, Trevi will present data highlights from ATS 2026 alongside Professor Philip Molyneaux and CDO James Cassella. The 11:30 a.m. to 1:15 p.m. ET session will feature detailed results on Haduvio’s statistically significant reductions in cough frequency across IPF, non-IPF ILD and RCC patient cohorts.